Given in RTOG 9601 that patients who had a pre-RT PSA <0.7 did not derive a survival benefit with ADT, why was other cause mortality evaluated in patients with PSA <0.6 as noted in this year's plenary?  

I am not sure the exact question as it could be interpreted as 1 of 2 things. 1. Was a different cutpoint used in the NEJM paper and in the ASTRO plenary? -No.  The median PSA of the trial was 0.6 ng/mL.  The NEJM used <0.7 (0.2-0.6) and the ASTRO plenary simply used < or = 0.6 (0....